Associated Papers
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Missense VKOR mutants exhibit severe warfarin resistance but lack VKCFD via shifting to an aberrantly reduced state.
Li S et al.
Blood Advances, 2023
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact.
Chiasson MA et al.
Elife, 2020
Role of Genetic Variations in the Hepatic Handling of Drugs.
Marin JJG et al.
International Journal of Molecular Sciences, 2020
The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population.
Bader L et al.
The Pharmacogenomics Journal, 2020
Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.
Shen G et al.
Journal of Thrombosis and Haemostasis : Jth, 2018
VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.
Mili FD et al.
Future Cardiology, 2018
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.
Kalman LV et al.
Clinical Pharmacology and Therapeutics, 2016
Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.
Lewis BC et al.
Pharmacogenetics and Genomics, 2016
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2016
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.
Duconge J et al.
Plos One, 2016
Structural Modeling Insights into Human VKORC1 Phenotypes.
Czogalla KJ et al.
Nutrients, 2015
[Resistance to acenocoumarol revealing a missense mutation of the vitamin K epoxyde reductase VKORC1: a case report].
Mboup MC et al.
Annales De Cardiologie Et D'angeiologie, 2015
Identification of VKORC1 genotype leading to resistance to tecarfarin.
Matagrin B et al.
Journal of Clinical Pharmacology, 2014
A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.
Bosch LA
Journal of Pharmacogenomics & Pharmacoproteomics, 2014
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.
Czogalla KJ et al.
Blood, 2013
Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
Kadian-Dodov DL et al.
Vascular Medicine (london, England), 2013
A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.
Fregin A et al.
Journal of Thrombosis and Haemostasis : Jth, 2013
VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity.
Hodroge A et al.
Journal of Thrombosis and Haemostasis : Jth, 2012
Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction.
Kurnik D et al.
Thrombosis and Haemostasis, 2012
Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
Valentin II et al.
The Annals of Pharmacotherapy, 2012
Pharmacogenetics, pharmacogenomics, and individualized medicine.
Ma Q et al.
Pharmacological Reviews, 2011
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
Watzka M et al.
Journal of Thrombosis and Haemostasis : Jth, 2011
Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing.
Rodríguez-Vélez R et al.
Puerto Rico Health Sciences Journal, 2010
CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.
Villagra D et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.
Maurice CB et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.
Lubitz SA et al.
Journal of Thrombosis and Haemostasis : Jth, 2010
[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].
Moreau C et al.
La Revue De Medecine Interne, 2010
Structure of a bacterial homologue of vitamin K epoxide reductase.
Li W et al.
Nature, 2010
Pharmacogenetics in cardiovascular antithrombotic therapy.
Marín F et al.
Journal of the American College of Cardiology, 2009
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA et al.
Pharmacogenomics, 2009
A new VKORC1 mutation leading to an isolated resistance to fluindione.
Peoc'h K et al.
British Journal of Haematology, 2009
Novel mutations in the VKORC1 gene of wild rats and mice--a response to 50 years of selection pressure by warfarin?
Rost S et al.
Bmc Genetics, 2009
Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
Duconge J et al.
Ethnicity & Disease, 2009
Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.
Harrington DJ et al.
Journal of Thrombosis and Haemostasis : Jth, 2008
A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon.
Wilms EB et al.
Journal of Thrombosis and Haemostasis : Jth, 2008
A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance.
Ainle FN et al.
Irish Journal of Medical Science, 2008
Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.
D'Andrea G et al.
Blood Reviews, 2008
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
Scott SA et al.
American Journal of Human Genetics, 2008
Building individualized medicine: prevention of adverse reactions to warfarin therapy.
Krynetskiy E et al.
The Journal of Pharmacology and Experimental Therapeutics, 2007
Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
Zhu Y et al.
Clinical Chemistry, 2007
A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme.
D'Ambrosio RL et al.
Journal of Thrombosis and Haemostasis : Jth, 2007
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T et al.
Thrombosis Research, 2007
[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
Loriot MA et al.
La Revue De Medecine Interne, 2006